Hans Basun

Nya antikroppsbehandlingar mot alzheimers sjukdom: Behov av nationell förberedelse och samordning

Granberg, Tobias; Börjesson Hanson, Anne; Fällmar, David; Basun, Hans et al.

Ingår i Läkartidningen, 2024

Nya antikroppsbehandlingar mot Alzheimers sjukdom: [New Alzheimer’s treatments: a need for national preparations and coordination]

Granberg, Tobias; Börjesson Hanson, Anne; Fällmar, David; Basun, Hans et al.

Ingår i Läkartidningen, 2024

Kognitiva sjukdomar

Basun, Hans; Kilander, Lena

Ingår i Psykiatri, Studentlitteratur AB, 2024

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Johannesson, Malin; Sahlin, Charlotte; Söderberg, Linda; Basun, Hans et al.

Ingår i Molecular and Cellular Neuroscience, 2021

• DOI för Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Alzheimers sjukdom – diagnostik och behandling i dag och i framtiden

Bogdanovic, Nenad; Hansson, Oskar; Zetterberg, Henrik; Basun, Hans et al.

Ingår i Läkartidningen, 2020

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Johannesson, Malin; Sahlin, Charlotte; Söderberg, Linda; Basun, Hans et al.

Ingår i Molecular and Cellular Neuroscience, 2021

• DOI för Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Alzheimers sjukdom – diagnostik och behandling i dag och i framtiden

Bogdanovic, Nenad; Hansson, Oskar; Zetterberg, Henrik; Basun, Hans et al.

Ingår i Läkartidningen, 2020

Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study

Jernerén, Fredrik; Cederholm, Tommy; Refsum, Helga; Smith, A. David et al.

Ingår i Journal of Alzheimer's Disease, s. 189-197, 2019

• DOI för Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study

Rapid amyloid-β oligomer and protofibril accumulation in traumatic brain injury

Abu Hamdeh, Sami; Rollman Waara, Erik; Möller, Christer; Söderberg, Linda et al.

Ingår i Brain Pathology, s. 451-462, 2018

• DOI för Rapid amyloid-β oligomer and protofibril accumulation in traumatic brain injury

Does Fatty Acid Composition in Subcutaneous Adipose Tissue Differ between Patients with Alzheimer's Disease and Cohabiting Proxies?

Faxen-Irving, Gerd; Falahati, Farshad; Basun, Hans; Eriksdotter, Maria et al.

Ingår i Journal of Alzheimer's Disease, s. 515-519, 2018

• DOI för Does Fatty Acid Composition in Subcutaneous Adipose Tissue Differ between Patients with Alzheimer's Disease and Cohabiting Proxies?

DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study

Karimi, Mohsen; Vedin, Inger; Levi, Yvonne Freund; Basun, Hans et al.

Ingår i American Journal of Clinical Nutrition, s. 1157-1165, 2017

• DOI för DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study

Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimer's Disease

Almkvist, Ove; Rodriguez-Vieitez, Elena; Thordardottir, Steinunn; Amberla, Kaarina et al.

Ingår i Journal of the International Neuropsychological Society, s. 195-203, 2017

• DOI för Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimer's Disease

High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease

Gunnarsson, Malin Degerman; Ingelsson, Martin; Blennow, Kaj; Basun, Hans et al.

Ingår i Alzheimer's Research & Therapy, 2016

• DOI för High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease
• Ladda ner fulltext (pdf) av High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease

Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective A beta antibody

Logovinsky, Veronika; Satlin, Andrew; Lai, Robert; Swanson, Chad et al.

Ingår i Alzheimer's Research & Therapy, 2016

• DOI för Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective A beta antibody
• Ladda ner fulltext (pdf) av Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective A beta antibody

Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study

Eriksdotter, Maria; Vedin, Inger; Falahati, Farshad; Freund-Levi, Yvonne et al.

Ingår i Journal of Alzheimer's Disease, s. 805-812, 2015

• DOI för Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study

Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study

Freund Levi, Y; Vedin, I; Cederholm, Tommy; Basun, Hans et al.

Ingår i Journal of Internal Medicine, s. 428-436, 2014

• DOI för Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study

Effects of Supplementation with Omega-3 Fatty Acids on Oxidative Stress and Inflammation in Patients with Alzheimer's Disease: The OmegAD Study

Freund-Levi, Yvonne; Vedin, Inger; Hjorth, Erik; Basun, Hans et al.

Ingår i Journal of Alzheimer's Disease, s. 823-831, 2014

• DOI för Effects of Supplementation with Omega-3 Fatty Acids on Oxidative Stress and Inflammation in Patients with Alzheimer's Disease: The OmegAD Study

High Tau Levels in Cerebrospinal Fluid Predict Rapid Decline and Increased Dementia Mortality in Alzheimer's Disease

Degerman Gunnarsson, Malin; Lannfelt, Lars; Ingelsson, Martin; Basun, Hans et al.

Ingår i Dementia and Geriatric Cognitive Disorders, s. 196-206, 2014

• DOI för High Tau Levels in Cerebrospinal Fluid Predict Rapid Decline and Increased Dementia Mortality in Alzheimer's Disease

Re-evaluation of clinical dementia diagnoses with pittsburgh compound B positron emission tomography

Degerman Gunnarsson, Malin; Lindau, M; Santillo, A F; Wall, Anders et al.

Ingår i Dementia and Geriatric Cognitive Disorders Extra, s. 472-481, 2013

• DOI för Re-evaluation of clinical dementia diagnoses with pittsburgh compound B positron emission tomography

The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ

Kalimo, Hannu; Lalowski, Maciej; Bogdanovic, Nenad; Philipson, Ola et al.

Ingår i Acta neuropathologica communications, s. 60, 2013

• DOI för The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ

Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia

Olsson, Bob; Hertze, Joakim; Lautner, Ronald; Zetterberg, Henrik et al.

Ingår i Journal of Alzheimer's Disease, s. 45-53, 2013

• DOI för Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia

Effects on Transthyretin in Plasma and Cerebrospinal Fluid by DHA-Rich n-3 Fatty Acid Supplementation in Patients with Alzheimer's Disease: The OmegAD Study

Faxen-Irving, Gerd; Freund-Levi, Yvonne; Eriksdotter-Jonhagen, Maria; Basun, Hans et al.

Ingår i Journal of Alzheimer's Disease, s. 1-6, 2013

• DOI för Effects on Transthyretin in Plasma and Cerebrospinal Fluid by DHA-Rich n-3 Fatty Acid Supplementation in Patients with Alzheimer's Disease: The OmegAD Study

Omega-3 Fatty Acids Enhance Phagocytosis of Alzheimer's Disease-Related Amyloid-beta(42) by Human Microglia and Decrease Inflammatory Markers

Hjorth, Erik; Zhu, Mingqin; Toro, Veronica Cortes; Vedin, Inger et al.

Ingår i Journal of Alzheimer's Disease, s. 697-713, 2013

• DOI för Omega-3 Fatty Acids Enhance Phagocytosis of Alzheimer's Disease-Related Amyloid-beta(42) by Human Microglia and Decrease Inflammatory Markers
• Ladda ner fulltext (pdf) av Omega-3 Fatty Acids Enhance Phagocytosis of Alzheimer's Disease-Related Amyloid-beta(42) by Human Microglia and Decrease Inflammatory Markers

Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia

Olsson, Bob; Hertze, Joakim; Ohlsson, Mattias; Nägga, Katarina et al.

Ingår i Journal of Alzheimer's Disease, s. 673-679, 2013

• DOI för Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia

Effects of DHA- Rich n-3 Fatty Acid Supplementation on Gene Expression in Blood Mononuclear Leukocytes: The OmegAD Study

Vedin, Inger; Cederholm, Tommy; Freund-Levi, Yvonne; Basun, Hans et al.

Ingår i PLOS ONE, 2012

• DOI för Effects of DHA- Rich n-3 Fatty Acid Supplementation on Gene Expression in Blood Mononuclear Leukocytes: The OmegAD Study
• Ladda ner fulltext (pdf) av Effects of DHA- Rich n-3 Fatty Acid Supplementation on Gene Expression in Blood Mononuclear Leukocytes: The OmegAD Study

Extreme Stability of Chitotriosidase in Cerebrospinal Fluid makes it a Suitable Marker for Microglial Activation in Clinical Trials

Olsson, Bob; Malmestrom, Clas; Basun, Hans; Annas, Peter et al.

Ingår i Journal of Alzheimer's Disease, s. 273-276, 2012

• DOI för Extreme Stability of Chitotriosidase in Cerebrospinal Fluid makes it a Suitable Marker for Microglial Activation in Clinical Trials

Longitudinal Stability Evaluation of Biomarkers and Their Correlation in Cerebrospinal Fluid and Plasma from Patients with Alzheimer's Disease

Höglund, Kina; Bogstedt, Anna; Fabre, Susanne; Aziz, Ali et al.

Ingår i Journal of Alzheimer's Disease, s. 939-947, 2012

• DOI för Longitudinal Stability Evaluation of Biomarkers and Their Correlation in Cerebrospinal Fluid and Plasma from Patients with Alzheimer's Disease

Influence of Lithium Treatment on GDNF Serum and CSF Concentrations in Patients with Early Alzheimer΄s Disease

Straten, Guido; Saur, Ralf; Laske, Christoph; Gasser, Thomas et al.

Ingår i Current Alzheimer research, s. 853-859, 2011

Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease

Wesnes, K; Edgar, C.; Andreasen, N.; Annas, P. et al.

Ingår i Acta Neurologica Scandinavica, s. 270-277, 2010

• DOI för Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease

Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls

Sundelöf, Johan; Sundström, Johan; Hansson, Oskar; Eriksdotter-Jönhagen, Maria et al.

Ingår i Journal of Alzheimer's Disease, s. 1223-1230, 2010

• DOI för Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls

Cystatin C Levels are Positively Correlated with both Aβ₄₂ and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls

Sundelöf, Johan; Sundstrom, Johan; Hansson, Oskar; Eriksdotter-Jönhagen, Maria et al.

Ingår i Journal of Alzheimer's Disease, s. 471-478, 2010

• DOI för Cystatin C Levels are Positively Correlated with both Aβ₄₂ and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls

Reduced prostaglandin F_2α release from blood mononuclear leukocytes after oral supplementation of ω3 fatty acids: the OmegAD study

Vedin, Inger; Cederholm, Tommy; Freund-Levi, Yvonne; Basun, Hans et al.

Ingår i Journal of Lipid Research, s. 1179-1185, 2010

• DOI för Reduced prostaglandin F_2α release from blood mononuclear leukocytes after oral supplementation of ω3 fatty acids: the OmegAD study

Systemic tocopherols and F2-isoprostanes and the risk of Alzheimer's disease and dementia: a prospective population-based study

Sundelöf, Johan; Kilander, Lena; Helmersson, Johanna; Larsson, Anders et al.

Ingår i Journal of Alzheimer's Disease, s. 71-78, 2009

• DOI för Systemic tocopherols and F2-isoprostanes and the risk of Alzheimer's disease and dementia: a prospective population-based study

Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study

Irving, Gerd Faxén; Freund-Levi, Yvonne; Eriksdotter-Jönhagen, Maria; Basun, Hans et al.

Ingår i Journal of The American Geriatrics Society, s. 11-17, 2009

• DOI för Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study

Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease

Leyhe, Thomas; Eschweiler, Gerhard W; Stransky, Elke; Gasser, Thomas et al.

Ingår i Journal of Alzheimer's Disease, s. 649-656, 2009

• DOI för Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease

Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study

Hampel, Harald; Ewers, Michael; Bürger, Katharina; Annas, Peter et al.

Ingår i Journal of Clinical Psychiatry, s. 922-931, 2009

Sällsynta mutationer leder till framtidens behandling

Ingelsson, Martin; Basun, Hans; Pettersson, Frida Ekholm; Kilander, Lena et al.

Ingår i Läkartidningen, s. 1396-1400, 2009

Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study

Freund-Levi, Yvonne; Hjorth, Erik; Lindberg, Catharina; Cederholm, Tommy et al.

Ingår i Dementia and Geriatric Cognitive Disorders, s. 481-490, 2009

• DOI för Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study

Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study

Sundelöf, Johan; Kilander, Lena; Helmersson, Johanna; Larsson, Anders et al.

Ingår i Journal of Alzheimer's Disease, s. 79-87, 2009

• DOI för Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study

Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation

Skoglund, Lena; Brundin, RoseMarie; Olofsson, Tommie; Kalimo, Hannu et al.

Ingår i Neurogenetics, s. 27-34, 2009

• DOI för Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation

Plasma β Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men: A Prospective, Population-Based Cohort Study

Sundelöf, Johan; Giedraitis, Vilmantas; Irizarry, Michael C; Sundström, Johan et al.

Ingår i Archives of Neurology, s. 256-63, 2008

• DOI för Plasma β Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men: A Prospective, Population-Based Cohort Study

Serum cystatin C and the risk of Alzheimer disease in elderly men

Sundelöf, Johan; Ärnlöv, J.; Ingelsson, E.; Sundström, J. et al.

Ingår i Neurology, s. 1072-1079, 2008

• DOI för Serum cystatin C and the risk of Alzheimer disease in elderly men

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms

Freund-Levi, Yvonne; Basun, Hans; Cederholm, Tommy; Faxén-Irving, Gerd et al.

Ingår i International Journal of Geriatric Psychiatry, s. 161-169, 2008

• DOI för Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms

Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study

Vedin, Inger; Cederholm, Tommy; Freund Levi, Yvonne; Basun, Hans et al.

Ingår i American Journal of Clinical Nutrition, s. 1616-1622, 2008

Clinical and Neuropathological Features of the Arctic APP Gene Mutation Causing Early-Onset Alzheimer Disease

Basun, Hans; Bogdanovic, Nenad; Ingelsson, Martin; Almkvist, Ove et al.

Ingår i Archives of Neurology, s. 499-505, 2008

• DOI för Clinical and Neuropathological Features of the Arctic APP Gene Mutation Causing Early-Onset Alzheimer Disease

Reduction of Phosphorylated Tau during Memantine Treatment of Alzheimer's Disease

Degerman Gunnarsson, Malin; Kilander, Lena; Basun, Hans; Lannfelt, Lars

Ingår i Dementia and Geriatric Cognitive Disorders, s. 247-252, 2007

• DOI för Reduction of Phosphorylated Tau during Memantine Treatment of Alzheimer's Disease

Underskatta inte värdet av transgena djurmodeller av Alzheimers sjukdom

Nilsson, Lars; Lannfelt, Lars; Basun, Hans; Nordberg, Agneta et al.

Ingår i Läkartidningen, s. 798-800, 2007

Longitudinal stability of CSF biomarkers in Alzheimer's disease

Blennow, Kaj; Zetterberg, Henrik; Minthon, Lennart; Lannfelt, Lars et al.

Ingår i Neuroscience Letters, s. 18-22, 2007

• DOI för Longitudinal stability of CSF biomarkers in Alzheimer's disease

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study - A randomized double-blind trial

Freund-Levi, Yvonne; Eriksdotter-Jonhagen, Maria; Cederholm, Tommy; Basun, Hans et al.

Ingår i Archives of Neurology, s. 1402-1408, 2006

• DOI för Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study - A randomized double-blind trial

Nutritional and cognitive relationships and long-term mortality in patients with various dementia disorders.

Faxén-Irving, Gerd; Basun, Hans; Cederholm, Tommy

Ingår i Age Ageing, s. 136-41, 2005

Nutrition education for care staff and possible effects on nutritional status in residents of sheltered accommodation.

Faxén-Irving, G; Andrén-Olsson, B; Geijerstam, A; Basun, H et al.

Ingår i Eur J Clin Nutr, s. 947-54, 2005

Konformationsförändrade proteiner orsakar neurodegenerativa sjukdomar

Ingelsson, Martin; Nilsson, Lars; Basun, Hans; Aquilonius, Sten-Magnus et al.

Ingår i Läkartidningen, s. 3542-3551, 2005

Clinical and molecular aspects of frontotemporal dementia.

Froelich-Fabre, Susanne; Skoglund, Lena; Ostojic, Jovanka; Kilander, Lena et al.

Ingår i Neurodegener Dis, s. 218-24, 2004

No evidence for tau duplications in frontal temporal dementia families showing genetic linkage to the tau locus in which tau mutations have not been found.

Johnson, J; Ostojic, J; Lannfelt, L; Glaser, A et al.

Ingår i Neurosci Lett, s. 99-101, 2004

The effect of nutritional intervention in elderly subjects residing in group-living for the demented.

Faxén-Irving, G; Andrén-Olsson, B; af Geijerstam, A; Basun, H et al.

Ingår i Eur J Clin Nutr, s. 221-7, 2002

Nya antikroppsbehandlingar mot alzheimers sjukdom: Behov av nationell förberedelse och samordning

Granberg, Tobias; Börjesson Hanson, Anne; Fällmar, David; Basun, Hans et al.

Ingår i Läkartidningen, 2024

Nya antikroppsbehandlingar mot Alzheimers sjukdom: [New Alzheimer’s treatments: a need for national preparations and coordination]

Granberg, Tobias; Börjesson Hanson, Anne; Fällmar, David; Basun, Hans et al.

Ingår i Läkartidningen, 2024

Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Matsunaga, Shinji; Kishi, Taro; Annas, Peter; Basun, Hans et al.

Ingår i Journal of Alzheimer's Disease, s. 403-410, 2015

• DOI för Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease

Lannfelt, Lars; Moller, Christer; Basun, Hans; Osswald, Gunilla et al.

Ingår i ALZHEIMERS RES THER, s. 16, 2014

• DOI för Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease
• Ladda ner fulltext (pdf) av Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease

Endpoints for trials in Alzheimer's disease: a European task force consensus.

Vellas, Bruno; Andrieu, Sandrine; Sampaio, Cristina; Coley, Nicola et al.

Ingår i Lancet Neurology, s. 436-450, 2008

• DOI för Endpoints for trials in Alzheimer's disease: a European task force consensus.

Disease-modifying trials in Alzheimer's disease: a European task force consensus.

Vellas, Bruno; Andrieu, Sandrine; Sampaio, Cristina; Basun, Hans et al.

Ingår i Lancet Neurology, s. 56-62, 2007

• DOI för Disease-modifying trials in Alzheimer's disease: a European task force consensus.

Kognitiva sjukdomar

Basun, Hans; Kilander, Lena

Ingår i Psykiatri, Studentlitteratur AB, 2024

Details of neuropathology in Arctic Alzheimer's disease

Kalimo, H.; Bogdanovic, N.; Callaghan, Paul O.; Bird, T. D. et al.

Ingår i Abstracts of the XVIIth International Congress of Neuropathology (ICN 2010), Salzburg, Austria, 11-15 September 2010, s. 22-23, 2010

• DOI för Details of neuropathology in Arctic Alzheimer's disease